2024-04-02 19:00:11 ET
Image source: The Motley Fool.
Ocugen (NASDAQ: OCGN)
Q4 2023 Earnings Call
Apr 02, 2024 , 8:30 a.m. ET
Operator
For further details see:
Ocugen (OCGN) Q4 2023 Earnings Call Transcript2024-04-02 19:00:11 ET
Image source: The Motley Fool.
Ocugen (NASDAQ: OCGN)
Q4 2023 Earnings Call
Apr 02, 2024 , 8:30 a.m. ET
Operator
For further details see:
Ocugen (OCGN) Q4 2023 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your X Account to Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years 100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one ...
OCU410 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis MALVERN, Pa., Dec. 19, 202...
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, an...